7 February 2019 - - Israeli generic drug developer Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) (TASE: TEVA) has launched ALYQ, a generic version of Adcirca (tadalafil) tablets, 20 mg in the US, the company said.

ALYQ is a phosphodiesterase 5 inhibitor indicated for the treatment of pulmonary arterial hypertension (WHO Group 1) to improve exercise ability. PAH is high blood pressure in the blood vessels of the lungs.

With over 550 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the US.

Currently, one in seven generic prescriptions dispensed in the US is filled with a Teva generic product.

Adcirca had annual total sales of approximately USD 490m in the US, according to IQVIA data as of November 2018.

ALYQ is indicated for the treatment of pulmonary arterial hypertension (WHO Group 1) to improve exercise ability. Studies establishing effectiveness included predominately patients with NYHA Functional Class II III symptoms and etiologies of idiopathic or heritable PAH or PAH associated with connective tissue diseases.

Teva Pharmaceutical Industries is in generic medicines, with innovative treatments in select areas, including CNS, pain and respiratory.